Vitamin D3, K2 & Calcium Homeostasis

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: Vitamin D3, K2 & Calcium Homeostasis - References

---

1. Pharmacodynamics & Mechanism of Action

The Vitamin D3–K2 axis acts as a dual-stage endocrine and enzymatic regulator of calcium trafficking, immune tolerance, and genomic transcription.

• Secosteroid VDR Signaling (Vitamin D3): Cholecalciferol undergoes hepatic 25-hydroxylation (CYP2R1) to calcifediol ($25(\text{OH}){\text{D}}_3$) and renal/paracrine $1\alpha$-hydroxylation (CYP27B1) to calcitriol ($1,25(\text{OH}{)}_2{\text{D}}_3$). Calcitriol binds the intracellular Vitamin D Receptor (VDR), heterodimerizes with the Retinoid X Receptor (RXR), and binds Vitamin D Response Elements (VDREs) across $>900$ human genes—upregulating intestinal calcium transporters (TRPV6, calbindin) and antimicrobial peptides (Immune & Thymic Peptides (Thymosin Alpha-1, LL-37)).
• Gamma-Glutamyl Carboxylase Activation (Vitamin K2): While calcitriol stimulates the synthesis of Osteocalcin (in osteoblasts) and Matrix Gla Protein (MGP) (in vascular smooth muscle cells), these proteins are secreted in an inactive undercarboxylated state (ucOC and dp-ucMGP). Vitamin K2 (menaquinone) serves as the obligate cofactor for $\gamma$-glutamyl carboxylase (GGCX), converting glutamate (Glu) residues into calcium-binding $\gamma$-carboxyglutamate (Gla) residues—routing calcium into hydroxyapatite bone matrix while inhibiting medial arterial calcification.

---

2. Pharmacokinetics & Isoform Profiles

• Cholecalciferol ($D_3$) vs. Ergocalciferol ($D_2$): Vitamin $D_3$ exhibits $87\%$ greater potency in raising and sustaining serum $25(\text{OH})\text{D}$ than $D_2$ due to higher affinity for Vitamin D Binding Protein (DBP) and slower catabolism via CYP24A1.
• Menaquinone-7 (MK-7) vs. Menaquinone-4 (MK-4):
  • MK-7: Bacterial fermentation-derived long-chain isoprenoid; incorporated into LDL/VLDL particles for prolonged systemic circulation ($t_{1/2}\approx 68\text{–}72\text{ hours}$), achieving steady-state extrahepatic carboxylation at microgram doses ($90\text{–}200\mu \text{g/day}$).
  • MK-4 (Menatetrenone): Short-chain isoprenoid rapidly cleared from plasma ($t_{1/2}\approx 1.5\text{ hours}$); activates the SXR/PXR nuclear receptor in osteoblasts and crosses the blood-brain barrier to support myelin sulfatide synthesis, requiring milligram-range split dosing ($1.5\text{–}45\text{ mg/day}$) for therapeutic bone density trials.

---

3. Dosing, Cycling & Synergies

• Standard Protocol:
  • Vitamin D3: $2,000\text{–}5,000\text{ IU/day}$ ($50\text{–}125\mu \text{g}$), titrated to maintain serum $25(\text{OH})\text{D}$ between $45\text{–}65\text{ ng/mL}$ ($112\text{–}162\text{ nmol/L}$).
  • Vitamin K2: $100\text{–}200\mu \text{g/day}$ all-trans MK-7 (often combined with $1,000\text{–}1,500\mu \text{g}$ MK-4).
• Timing: Administer with a meal containing $\ge 15\text{ g}$ of dietary fat (increases micellar absorption by $+32\%$). Avoid late-night high-dose D3 if subjective melatonin suppression is observed.
• Synergies: Magnesium Forms & Bioavailability (required cofactor for CYP2R1, CYP27B1, and DBP binding; $\text{Mg}$ deficiency causes “Vitamin D resistance”), Vitamin A (retinol/retinoic acid for RXR heterodimer balance), and Boron ($3\text{–}6\text{ mg/day}$, inhibits CYP24A1 catabolism of $25(\text{OH})\text{D}$).
• Contraindications & Biomarkers to Monitor:
  • Contraindications: Vitamin K antagonists (warfarin/coumarins—strictly contraindicated with K2), primary hyperparathyroidism, granulomatous diseases (sarcoidosis). Note: Direct Oral Anticoagulants (DOACs like apixaban/rivaroxaban) do not act via Vitamin K epoxide reductase.
  • Biomarkers: Serum 25(OH)D, Intact PTH (suppressed plateau indicates functional sufficiency), Serum Calcium, Ionized Calcium, and undercarboxylated osteocalcin (ucOC/cOC ratio) or dp-ucMGP.

---

4. Key Scientific Evidence Summary

• Skeletal Preservation & Carboxylation: Knapen et al. (2013) demonstrated in a 3-year RCT ($N=244$) that $180\mu \text{g/day}$ MK-7 reduced circulating ucOC by $-58\%$ and significantly attenuated age-related declines in lumbar spine and femoral neck bone mineral content and strength.
• Arterial Stiffness Reversal: Knapen et al. (2015) showed in Thrombosis and Haemostasis that 3 years of $180\mu \text{g/day}$ MK-7 decreased inactive dp-ucMGP by $-50\%$ and significantly improved carotid-femoral pulse wave velocity (Stiffness Index $\beta$) in postmenopausal women.
• Vascular Intima-Media Protection: Kurnatowska et al. (2015) and van Ballegooijen et al. (2017) confirmed synergistic reductions in carotid intima-media thickness (CCA-IMT) and coronary calcification progression when pairing Vitamin D3 with MK-7 versus D3 monotherapy.

See full study breakdowns in Vitamin D3, K2 & Calcium Homeostasis - References.